Invitae Corp
0.0 %
0.0 %
Yet to be announced
Company Overview
Invitae Corporation is a medical genetics company that integrates genetic testing, counseling, and healthcare information into a single service to support healthcare providers in caring for their patients. The company offers diagnostic, proactive, and preimplantation genetic testing, as well as genetic counseling services.
The company's core business involves genetic testing services for various conditions including hereditary cancer, neurological disorders, cardiovascular disorders, and rare diseases. They use advanced medical genetics technology to provide comprehensive health assessments.
Revenue Sources
PassBased on SEC filings and the company's financial reports, Invitae's primary revenue streams come from genetic testing services and related healthcare activities. These activities are permissible from an Islamic perspective as they provide valuable medical services that help diagnose and prevent diseases. There is no evidence of revenue from prohibited sources.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2023 | $121.24m | $1.11b | - | $5.62m | 0.00% | 0.51% |
| June 30, 2023 | $120.53m | $353.01m | - | $6.02m | 0.00% | 1.71% |
| March 31, 2023 | $117.36m | $315.05m | - | $22.32m | 0.00% | 7.08% |
| Dec. 31, 2022 | $122.45m | $231.95m | - | $14.6m | 0.00% | 6.29% |
Looking at the last four quarters, interest expenses have been consistently high relative to total expenses. The ratio of interest expense to total expenses exceeds acceptable thresholds, indicating that interest-based financing plays a material role in the company's operations.
Operational Ethics
PassBased on available information from SEC filings and company reports, there is no evidence of significant ongoing associations with entities involved in human rights violations. The company primarily operates in the United States and partners with healthcare providers and research institutions.
Comments